Skip to content

O2 Tension During TAVI

Effect of O2 Tension on Myocardial Injury During TAVI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03291210
Enrollment
72
Registered
2017-09-25
Start date
2017-10-18
Completion date
2022-07-18
Last updated
2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Troponin

Keywords

hyperoxemia, myocardial injury, transcatheter aortic valve replacement

Brief summary

Hyperoxemia can produce various complications including oxidative stress and myocardial injury. We hypothesized that the normoxic group would have lower myocardial injury compared to hyperoxic group after transcatheter aortic valve replacement.

Detailed description

Hyperoxemia can produce various complications, such as excessive oxidative stress, hyperoxia-induced vasoconstriction, increased perfusion heterogeneity, and resultant myocardial injury. Previous studies have been observed higher mortality in patient group maintained with supranormal oxygenation after resuscitation from cardiac arrest. However, the effect of hyperoxia vs. normoxia on myocardial injury during transcatheter aortic valve replacement (TAVR) has not been well investigated. We hypothesized that the normoxic group would have lower myocardial injury compared to hyperoxic group after TAVR.

Interventions

OTHERnormal inspired oxygen fraction

receives inspired oxygen fraction of 0.3

OTHERhigh inspired oxygen fraction

receives inspired oxygen fraction of 0.8

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled for transcatheter aortic valve replacement due to aortic stenosis

Exclusion criteria

* Transapical approach * Pre-procedural PaO2 \< 65 mmHg or oxygen support therapy * Pre-procedural severe kidney injury (end-stage renal disease) * Pre-procedural chronic pulmonary disease, symptomatic asthma * Pre-procedural Tb-destroyed lung * Lung cancer * History of acute coronary syndrome within 6 months * Pre-procedural elevated Troponin I or CKMB * History of stroke or transient ischemic attack within 6 months * Refuse to participate * Pregnant

Design outcomes

Primary

MeasureTime frameDescription
Troponin I72 hours after the end of procedureArea under the curve of troponin I

Secondary

MeasureTime frameDescription
CK MB72 hours after the end of procedureArea under the curve of CK MB
Changes in cerebral oximetrythrough procedure completion, an average of 3 hourschanges in cerebral oximetry during the procedure
Delirumthrough admission completion, an average of 5 daysNewly onset delirium
AKI or RRTthrough admission completion, an average of 5 daysNewly onset acute kidney injury or renal replacement therapy
stroke, myocardial infarction or mortalitythrough admission completion, an average of 5 daysNewly onset stroke, myocardial infarction or mortality

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026